Search results for "FDA update"


 
Results 41 - 50 of about 55 for "FDA update".

First drug in new class approved

The FDA recently approved canaglifozin (Invokana) tablets to improve glycemic control in adults with type 2 diabetes, along with diet and exercise. ... The FDA is requiring five postmarketing studies: a cardiovascular outcomes trial; an enhanced
June 2013

Another weight loss drug approved

A combination of phentermine and topiramate extended-release (Qsymia) was recently approved by the FDA as an addition to a reduced-calorie diet and exercise for chronic weight management.
October 2012

Empagliflozin approved to treat type 2 diabetes

Empagliflozin (Jardiance), a sodium glucose co-transporter 2 inhibitor, was recently approved to treat type 2 diabetes in addition to diet and exercise, the FDA announced last week. ... The FDA is requiring 4 postmarketing studies to investigate
August 2014

New drug approved, meters recalled

Dapaglifozin (Farxiga), a new medication to treat type 2 diabetes, was recently approved by the FDA for use along with diet and exercise. ... The FDA also announced a recall of some TRUEbalance and TRUEtrack blood glucose meters by Nipro Diagnostics, Inc.
March 2014

New warnings on medications containing saxagliptin, alogliptin

New warnings will be placed on saxagliptin and alogliptin about the potential risk of heart failure, particularly in patients with heart or kidney disease, the FDA announced on April 5. ... The FDA recommends that clinicians consider discontinuing
April 2016

New GLP-1 agonist approved

A new glucagon-like peptide-1 (GLP-1) receptor agonist, dulaglutide (Trulicity), was approved to treat type 2 diabetes, along with diet and exercise, the FDA recently announced. ... The FDA is requiring several postmarketing studies, including trials in
October 2014

Liraglutide gets new cardiovascular indication

The FDA approved a new indication for liraglutide to reduce the risk of myocardial infarction, stroke, and cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. ... The FDA recently approved a new indication for
September 2017

Single and combo diabetes drugs approved

Alogliptin (Nesina) and two new combination drugs (alogliptin and metformin hydrochloride [Kazano] and alogliptin and pioglitazone [Oseni]) were approved by the FDA to improve blood glucose control in adults with type ... The FDA is requiring five
May 2013

Warning about serious genital infections in patients taking SGLT2 inhibitors

The FDA has identified 12 cases of necrotizing fasciitis of the perineum or Fournier's gangrene. ... The FDA warned on Aug. 29 that cases of a rare, serious infection of the genitals and surrounding area have been reported in patients taking
September 2018

Recall, warning, and a new generic drug

Certain batches of NovoPen Echo insulin cartridge holders are being recalled by the manufacturer because they may crack or break if exposed to certain chemicals, such as cleaning agents, the FDA ... The FDA also announced on May 19 that it approved the
July 2017

Result Page: Prev   1   2   3   4   5   6   Next